Apogee Therapeutics/$APGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Ticker
$APGE
Sector
Primary listing
Employees
196
Headquarters
Website
APGE Metrics
BasicAdvanced
$2.2B
-
-$4.12
1.44
-
Price and volume
Market cap
$2.2B
Beta
1.44
52-week high
$50.56
52-week low
$26.20
Average daily volume
482K
Financial strength
Current ratio
16.358
Quick ratio
16.15
Long term debt to equity
1.101
Total debt to equity
1.751
Profitability
EBITDA (TTM)
-270.098
Effective tax rate (TTM)
-0.07%
Management effectiveness
Return on assets (TTM)
-23.21%
Return on equity (TTM)
-34.12%
Valuation
Price to book
3.48
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-9.377
Free cash flow yield (TTM)
-10.66%
Free cash flow per share (TTM)
-3.929
Growth
Earnings per share change (TTM)
71.06%
Bulls say / Bears say
As of March 31, 2025, Apogee held $681.4 million in cash, cash equivalents, and marketable securities, providing funding through at least Q1 2028 and supporting continued pipeline progress without immediate financing needs (SEC).
Part A of the Phase 2 APEX trial for APG777 met all primary and key secondary endpoints, delivering an EASI-75 rate of 66.9% (42.5% placebo-adjusted) at Week 16—representing the highest topline efficacy seen to date in any global biologic atopic dermatitis study (Apogee Therapeutics).
Interim Phase 1b data for APG808 showed rapid and robust FeNO reduction—53% maximum, and sustained 50% at 12 weeks—demonstrating the potential for best-in-class IL-4Rα blockade in asthma, with dosing intervals of two months or more (Apogee Therapeutics).
Apogee’s cash burn remains elevated, with a net loss of $55.3 million and negative operating cash flows of $48.5 million in Q1 2025, reflecting substantial ongoing R&D spending and significant cash usage (SEC).
All of Apogee’s candidates remain in early-stage clinical development with no approved products; the company’s disclosures highlight that failing to secure more funding or achieve development milestones could lead to delays or program terminations (SEC).
Apogee faces intense competition in atopic dermatitis and the broader immunology market from established leaders like Sanofi/Regeneron’s Dupixent, which generated €13 billion in revenue and sets a high bar for efficacy and market adoption—making differentiation and commercialization difficult (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
APGE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apogee Therapeutics stock?
Apogee Therapeutics (APGE) has a market cap of $2.2B as of September 18, 2025.
What is the P/E ratio for Apogee Therapeutics stock?
The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of September 18, 2025.
Does Apogee Therapeutics stock pay dividends?
No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Apogee Therapeutics dividend payment date?
Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Apogee Therapeutics?
Apogee Therapeutics (APGE) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.